Calendar

Dec
11
Wed
2019
AIMI, IBIIS & RSL Special Seminar - John Stafford & Bjorn Carey @ Clark Center - S360
AIMI, IBIIS & RSL Special Seminar – John Stafford & Bjorn Carey
Dec 11 @ 10:00 am – 11:00 am Clark Center - S360
AIMI, IBIIS & RSL Special Seminar - John Stafford & Bjorn Carey @ Clark Center - S360

“Messaging in the Age of Microtargeting”

John Stafford
Assistant Vice President
Digital Strategy
Stanford University

Bjorn Carey
Senior Director
Digital Strategy
Stanford University

Join via Zoom: https://stanford.zoom.us/j/400566542

Abstract:
Communications has become increasingly data-driven, targeted, and personalized. This has changed how Stanford analyzes communications opportunities from a research perspective and how it engages with relevant audiences. In this presentation, John and Bjorn will share the data and communications strategy underlying three communications initiatives and the resulting execution. They will also provide practical advice for individual thought leadership and communications in this dynamic environment.

About:
John Stafford, MA ’06, is currently Assistant Vice President for Digital Strategy at Stanford, the most senior digital communications role in the university. John is responsible for all aspects of creating a world-class digital communications function: setting the group’s strategy, building analytics and insight programs, counseling on crisis communications, leading multi-channel messaging initiatives, and advising colleagues across the University. He received a Master’s Degree in Communication from Stanford, a B.A. in History from the University of San Francisco, and was a founding advisor to Stanford Medicine X.

Refreshments will be provided.

Jan
23
Thu
2020
Early Detection Seminar Series - Victoria Seewaldt, M.D. @ Beckman Center, Munzer Auditorium (B060)
Early Detection Seminar Series – Victoria Seewaldt, M.D.
Jan 23 @ 11:00 am – 12:00 pm Beckman Center, Munzer Auditorium (B060)
Early Detection Seminar Series - Victoria Seewaldt, M.D. @ Beckman Center, Munzer Auditorium (B060)

CEDSS: “Strategies to Identify Aggressive Breast Cancer Biology in Black and Latina Women”

Victoria Seewaldt, MD
Ruth Ziegler Professor and Chair, Department of Population Sciences
Associate Director for Population Sciences Research, Comprehensive Cancer Center
City of Hope

Beckman Center, Munzer Auditorium (B060)
11:00am – 12:00pm Seminar & Discussion
12:00pm – 12:15pm Reception & Light Refreshments
RSVP here: https://www.onlineregistrationcenter.com/VictoriaSeewaldt

ABSTRACT

Over 90% of breast cancer is cured; yet there remain highly aggressive breast cancers that develop rapidly and are extremely difficult to treat, much less prevent. Examples are triple-negative breast cancer in Black/African American women and luminal B breast cancers in Black/African Americans and Latinas. Breast cancers that rapidly develop between breast imaging are called “interval cancers”. Here we aim to investigate biologically aggressive precancerous breast lesions and their matched invasive breast cancers in women of diverse race and ethnicity. Our team has the unique ability to perform single cell in situ transcriptional profiling in combination with dynamic and spatial genomics/proteomics; this allows us to identify multi-dimensional spatial and temporal relationships that drive the transition from biologically aggressive pre-cancer to interval breast cancer.

 

ABOUT

Victoria Seewaldt, M.D., is an accomplished clinician and researcher who’s devoted to improving the lives of her patients and the community at large. She has led community outreach education efforts on cancer prevention through personal wellbeing and directed research aimed at finding biomarkers that can be used for early cancer detection, particularly triple-negative breast cancers that are especially resistant to treatment.

At City of Hope, Dr. Seewaldt will direct efforts to provide breast cancer education, free breast cancer screening and treatment, mentorship of young minority scholars, and a forum for community partnered trials. Clinically, Dr. Seewaldt aims to empower women at high breast cancer risk to be full partners in developing wellness strategies to promote personal health.

Dr. Seewaldt received her medical degree from the University of California, Davis, and completed her residency and clinical fellowship at the University of Washington in Seattle. She then pursued a medical oncology fellowship with the Fred Hutchinson Cancer Research Center and then became an assistant professor at Ohio State University. Afterwards, she transferred to Duke University, where she held various clinical, academic and leadership roles in its School of Medicine and Comprehensive Cancer Center — most recently as a professor, co-leader of the breast and ovarian cancer program and head of the cancer breast prevention program — before joining City of Hope.

Mar
19
Thu
2020
CANCELLED - Cancer Early Detection Seminar Series - Azra Raza, M.D. @ CANCELLED
CANCELLED – Cancer Early Detection Seminar Series – Azra Raza, M.D.
Mar 19 @ 11:00 am – 12:30 pm CANCELLED
CANCELLED - Cancer Early Detection Seminar Series - Azra Raza, M.D. @ CANCELLED

Please note this seminar is now cancelled and will be rescheduled for a future date. Please contact Ashley Williams (ashleylw@stanford.edu) with any questions or concerns. Thank you for your understanding!

CEDSS: “The First Cell and the Human Cost of going after Cancer’s last”

Azra Raza, MD

Chan Soon-Shiong Professor of Medicine

Director, Myelodysplastic Syndrome Center

Columbia University Medical Center

Apr
22
Wed
2020
CANCELLED - IMAGinING THE FUTURE - Elias Zerhouni, M.D. @ CANCELLED
CANCELLED – IMAGinING THE FUTURE – Elias Zerhouni, M.D.
Apr 22 @ 1:00 pm – 2:30 pm CANCELLED
CANCELLED - IMAGinING THE FUTURE - Elias Zerhouni, M.D. @ CANCELLED

Please note this seminar is now cancelled and will be rescheduled for a future date. Please contact Ashley Williams (ashleylw@stanford.edu) with any questions or concerns. Thank you for your understanding!

 

IMAGinING THE FUTURE: “Journey Through Academia, Government and Industry: Lessons Learned”

Elias Zerhouni, M.D.

Professor Emeritus

John Hopkins University

 

May
26
Tue
2020
Cancer Early Detection Seminar Series - Eric Fung, M.D., Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Eric Fung, M.D., Ph.D.
May 26 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Eric Fung, M.D., Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: “Multicancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay”

Eric Fung, M.D., Ph.D.

Senior Medical Director

GRAIL, Inc.

Please see zoom details below:
Meeting URL: https://stanford.zoom.us/j/230531527
Dial: +1 650 724 9799 (US, Canada, Caribbean Toll) or +1 833 302 1536 (US, Canada, Caribbean Toll Free)
Meeting ID: 230 531 527

ABOUT

Dr. Eric Fung is Vice President, Clinical Development at GRAIL, where he leads several clinical development programs in support of the development of a blood-based multi-cancer detection test. Dr. Fung has previously held clinical development and R&D leadership roles at Affymetrix, Vermillion, Ciphergen, and Roche Molecular Diagnostics. Dr. Fung has led clinical trials leading to FDA clearance of multiple IVD products. Dr. Fung received his MD, PhD from the Johns Hopkins University School of Medicine.

 

Hosted by: Sanjiv Sam Gambhir, M.D., Ph.D.
Spon
sored by the Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Oct
6
Tue
2020
Early Detection of Cancer Conference @ Virtual Event
Early Detection of Cancer Conference
Oct 6 – Oct 8 all-day Virtual Event
Early Detection of Cancer Conference @ Virtual Event

Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, present the Early Detection of Cancer Conference series. The annual Conference brings together experts in early detection from multiple disciplines to share ground breaking research and progress in the field.

The Conference is part of a long-term commitment to invest in early detection research, to understand the biology behind early stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.

The 2020 conference will take place October 6-8 virtually.

 

Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, have been closely monitoring developments relating to the coronavirus (COVID-19) outbreak and reviewing guidance from government bodies. After careful consideration, we have made the decision to convert the Early Detection of Cancer Conference 2020 to a virtual conference, instead of the scheduled in-person conference on October 6-8 in London, UK. 

 

For more information visit the website: http://earlydetectionresearch.com/

Oct
15
Thu
2020
Cancer Early Detection Seminar Series - Paul Boutros, Ph.D., M.B.A. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Paul Boutros, Ph.D., M.B.A.
Oct 15 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Paul Boutros, Ph.D., M.B.A. @ Zoom - See Description for Zoom Link

CEDSS: “The Origins and Detection of Lethal Prostate Cancer”

Paul Boutros, Ph.D., M.B.A.
Director, Cancer Data Sciences
UCLA

Please see zoom details below:
Meeting URL: https://stanford.zoom.us/s/93515779500
Dial: +1 650 724 9799 or +1 833 302 1536
Meeting ID: 935 1577 9500
Meeting Passcode: 767148

ABOUT
Boutros earned his B.Sc. degree from the University of Waterloo in Chemistry in 2004, and his Ph.D. degree from the University of Toronto, Canada, in Medical Biophysics in 2008. At Toronto, he also earned an executive M.B.A. from the Rothman School of Management. In 2008, Boutros started his independent research career at the Ontario Institute for Cancer Research first as a fellow (2008–2010) and then as principal investigator (2010–2018). He moved to California to join the UCLA faculty in 2018.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by the Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Jan
19
Tue
2021
Cancer Early Detection Seminar Series - Thomas Kislinger, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Thomas Kislinger, Ph.D.
Jan 19 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Thomas Kislinger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: Systematic identification of fluid-based biomarkers for ovarian and prostate cancer

 

Thomas Kislinger, Ph.D.
Professor & Chair
Department of Medical Biophysics
University of Toronto

Senior Scientist
Princess Margaret Cancer Centre

 

Zoom Webinar Details 
Meeting URL: https://stanford.zoom.us/s/94878578384
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 948 7857 8384
Passcode: 692692
Register Here

 

ABOUT

Thomas Kislinger received his MSc in Analytical Chemistry from the University of Munich, Germany (1998). He completed his PhD in 2001, investigating the role of Advanced Glycation Endproducts in diabetic vascular complications at the University of Erlangen, Germany and Columbia University, New York. Between 2002 and 2006 he completed a post-doctoral fellowship at the University of Toronto. In 2006 he joined the Princess Margaret Cancer Centre as an independent investigator. Dr. Kislinger holds positions as Senior Scientist at the Princess Margaret Cancer Centre and as Professor and Chair at the University of Toronto in the Department of Medical Biophysics. The Kislinger lab applies proteomics technologies to translational and basic cancer biology. This includes the development of novel proteomics methodologies, identification of liquid biopsy signatures and the molecular identification of novel cell surface markers.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Mar
2
Tue
2021
Cancer Early Detection Seminar Series - Melissa Wong, Ph.D. @ Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series – Melissa Wong, Ph.D.
Mar 2 @ 11:00 am – 12:00 pm Zoom - See Description for Zoom Link
Cancer Early Detection Seminar Series - Melissa Wong, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response

Melissa Wong, Ph.D.
Associate Professor and Vice Chair
Department of Cell, Development and Cancer Biology
Program Co-Lead, Knight Cancer Institute
Oregon Health & Science University

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/98184098662
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 981 8409 8662
Passcode: 084321

RSVP Here!

 

ABSTRACT

Metastatic progression defines the final stages of tumor evolution and underlies the majority of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable of seeding and growing in distant organ sites contributes to the development of treatment resistant disease.  We recently reported the identification of a novel tumor-derived cell population, circulating hybrid cells (CHCs), harboring attributes from both macrophages and neoplastic cells, including functional characteristics important to metastatic spread. These disseminated hybrids outnumber conventionally defined circulating tumor cells (CTCs) in cancer patients. It is unknown if CHCs represent a generalized cancer mechanism for cell dissemination, or if this population is relevant to the metastatic cascade. We detect CHCs in the peripheral blood of patients with cancer in myriad disease sites encompassing epithelial and non-epithelial malignancies. Further, we demonstrate that in vivo-derived hybrid cells harbor tumor-initiating capacity in murine cancer models and that CHCs from human breast cancer patients express stem cell antigens, features consistent with the ability to seed and grow at metastatic sites. We reveal heterogeneity of CHC phenotypes reflect key tumor features, including oncogenic mutations and functional protein expression. Importantly, this novel population of disseminated neoplastic cells opens a new area in cancer biology and renewed opportunity for battling metastatic disease.

 

ABOUT

The research focus of the Wong laboratory revolves around understanding the regulatory mechanisms that control epithelial stem cell homeostasis and their expansion in developmental, homeostasis and disease contexts, including cancer. I have substantial training and experience in intestinal stem cell investigation leveraging in vivo and ex vivo modeling, as well as in myriad cutting edge technologies (i.e. cyCIF, scRNA-seq). My publication record spans my post-doctoral fellowship in Dr. Jeffrey Gordon’s laboratory at Washington University School of Medicine, to studies in my own laboratory at Oregon Health & Science University. Our research impacts the understanding of regulatory mechanisms that govern cell state in the context of the evolving tissue microenvironment and changing cell signaling landscape, in development and disease.

 

Our studies in stem cell regulation led to the intriguing finding that stem cells can fuse with tissue macrophages in the context of injury repair and may impact tissue regeneration. We have extended these findings to the cancer setting, where cancer-macrophage fusions are detectible in primary and metastatic tumors, and my group recently identified and characterized these cells as a novel circulating tumor cell population. Importantly, our studies in cell culture, in mice and humans provide an indepth evaluation of hybrid cells to set the foundation for continued investigations into their biology, impact on disease progression or tissue regeneration, and use as a biomarker for disease burden. Importantly, we coined the term, circulating hybrid cell (CHC) for this novel population and reported they exist at higher levels than conventionally defined circulating tumor cells in the peripheral blood of cancer patients. This work was published in 2018 and highlighted by Science Magazine as one of the top ten publications in the cancer field in the science family journals. The science proposed in this U01 application leverage hybrid cell biology to assess treatment response and resistance in breast cancer patients undergoing targeted therapy. Our proposal leverages active collaborations with Dr. Young Hwan Young’s group to synergize biology with computation, as well as a number of other valuable collaborators to ensure success of the proposed, cutting-edge science.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Apr
30
Fri
2021
Racial Equity Challenge: Race in society @ Zoom
Racial Equity Challenge: Race in society
Apr 30 @ 12:00 pm – 1:00 pm Zoom
Racial Equity Challenge: Race in society @ Zoom

Targeted violence continues against Black Americans, Asian Americans, and all people of color. The department of radiology diversity committee is running a racial equity challenge to raise awareness of systemic racism, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles, podcasts, videos, etc., from which they can choose, with the “challenge” of engaging with one to three media sources prior to our session (some videos are as short as a few minutes). Participants will meet in small-group breakout sessions to discuss what they’ve learned and share ideas.

Please reach out to Marta Flory, flory@stanford.edu with questions. For details about the session, including recommended resources and the Zoom link, please reach out to Meke Faaoso at mfaaoso@stanford.edu.